Studying the role of alveolar exhaled nitric oxide in combination with bronchial nitric oxide to predict asthma control in children with asthma: A real-life prospective study

IF 0.2 Q4 RESPIRATORY SYSTEM

Current Respiratory Medicine Reviews Pub Date : 2022-10-10 DOI:10.2174/1573398x18666221010112508

S. Duong-Quy, Thuy Nguyen-Thi-Dieu, Hanh Do-Thi, Huong Nguyen-Thi-Quynh, H. Le-Thi-Minh

{"title":"Studying the role of alveolar exhaled nitric oxide in combination with bronchial nitric oxide to predict asthma control in children with asthma: A real-life prospective study","authors":"S. Duong-Quy, Thuy Nguyen-Thi-Dieu, Hanh Do-Thi, Huong Nguyen-Thi-Quynh, H. Le-Thi-Minh","doi":"10.2174/1573398x18666221010112508","DOIUrl":null,"url":null,"abstract":"\n\nFractional exhaled nitric oxide (FENO) is currently used as a biomarker of\nairway inflammation in patients with asthma. However, the role of alveolar nitric oxide (CANO) in\nasthmatic children has not been clearly demonstrated\n\n\n\nIt was a prospective and descriptive study. The measurement of FENO and CANO, spirometry, blood eosinophil counts (BEC), and total IgE levels were performed for each study subject.\n\n\n\nThis study included 109 uncontrolled asthmatic children without inhaled corticosteroid\n(ICS) treatment. The exhaled NO level in asthmatic patients was significantly higher than in control\nsubjects: FENO: 22.5 vs. 8.4 ppb; CANO: 5.9 vs. 2.8 ppb; J’awNO (maximum airway nitric oxide\nflux): 56.9 vs. 18.7 ppb; respectively. The sensitivities and specificities for asthma diagnosis with\nthe cut-off of CANO at 3.5 ppb and 5.0 ppb were 74.3% and 73.3%, and 46.0% and 83.3%, respectively. There were the moderate and the weak correlations between CANO with FENO and CANO\nwith IgE in asthmatic patients (r = 0.465, 95%CI (0.133-0.659), P=0.001; r=0.133, 95%CI (0.068-\n0.497), P=0.184; respectively). The percentage of controlled asthma in patients with CANO ≥5 ppb\nat inclusion was higher than that in CANO <5 ppb group.\n\n\n\nExhaled NO is a relevant biomarker of allergic asthma. The level of FENO and CANO\nmight be used to predict asthma control in children.\n","PeriodicalId":44030,"journal":{"name":"Current Respiratory Medicine Reviews","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Respiratory Medicine Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573398x18666221010112508","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Fractional exhaled nitric oxide (FENO) is currently used as a biomarker of airway inflammation in patients with asthma. However, the role of alveolar nitric oxide (CANO) in asthmatic children has not been clearly demonstrated It was a prospective and descriptive study. The measurement of FENO and CANO, spirometry, blood eosinophil counts (BEC), and total IgE levels were performed for each study subject. This study included 109 uncontrolled asthmatic children without inhaled corticosteroid (ICS) treatment. The exhaled NO level in asthmatic patients was significantly higher than in control subjects: FENO: 22.5 vs. 8.4 ppb; CANO: 5.9 vs. 2.8 ppb; J’awNO (maximum airway nitric oxide flux): 56.9 vs. 18.7 ppb; respectively. The sensitivities and specificities for asthma diagnosis with the cut-off of CANO at 3.5 ppb and 5.0 ppb were 74.3% and 73.3%, and 46.0% and 83.3%, respectively. There were the moderate and the weak correlations between CANO with FENO and CANO with IgE in asthmatic patients (r = 0.465, 95%CI (0.133-0.659), P=0.001; r=0.133, 95%CI (0.068- 0.497), P=0.184; respectively). The percentage of controlled asthma in patients with CANO ≥5 ppb at inclusion was higher than that in CANO <5 ppb group. Exhaled NO is a relevant biomarker of allergic asthma. The level of FENO and CANO might be used to predict asthma control in children.

查看原文本刊更多论文

研究肺泡呼出一氧化氮联合支气管一氧化氮预测哮喘儿童哮喘控制的作用:一项现实前瞻性研究

呼气一氧化氮分数(FENO)目前被用作哮喘患者气道炎症的生物标志物。然而，肺泡型一氧化氮(CANO)在哮喘儿童中的作用尚未得到明确证实。对每个研究对象进行FENO和CANO、肺活量测定、血嗜酸性粒细胞计数(BEC)和总IgE水平的测量。本研究纳入109名未接受吸入皮质类固醇(ICS)治疗的未控制哮喘儿童。哮喘患者呼出NO水平显著高于对照组:FENO: 22.5 vs. 8.4 ppb;CANO: 5.9 vs. 2.8 ppb;J 'awNO(最大气道一氧化氮通量):56.9 vs. 18.7 ppb;分别。CANO截止值为3.5 ppb和5.0 ppb时，哮喘诊断的敏感性和特异性分别为74.3%和73.3%，46.0%和83.3%。哮喘患者CANO与FENO、CANO与IgE之间存在中、弱相关性(r = 0.465, 95%CI (0.133 ~ 0.659)， P=0.001;r=0.133, 95%CI (0.068 ~ 0.497)， P=0.184;分别)。CANO≥5ppb组哮喘控制率高于CANO < 5ppb组。呼出一氧化氮是过敏性哮喘的相关生物标志物。FENO和cano的水平可能用于预测儿童哮喘的控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Respiratory Medicine Reviews RESPIRATORY SYSTEM-

CiteScore

0.60

自引率

0.00%

发文量

期刊介绍： Current Respiratory Medicine Reviews publishes frontier reviews on all the latest advances on respiratory diseases and its related areas e.g. pharmacology, pathogenesis, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in respiratory medicine.